Effect of cytokine and pharmacogenomic genetic polymorphisms in transplantation

Current Opinion in Immunology

Volumn 20, Issue 5, 2008, Pages 614-625

  Girnita, Diana M ^a   Burckart, Gilbert ^b   Zeevi, Adriana ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; CYTOKINE RECEPTOR; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 6; MERCAPTOPURINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISOLONE; PREDNISONE; RAPAMYCIN; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ACUTE GRAFT REJECTION; BRONCHIOLITIS OBLITERANS; CHRONIC GRAFT REJECTION; DIARRHEA; DISEASE SEVERITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GENE; GENETIC POLYMORPHISM; GRAFT FAILURE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEART TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; HYPERTENSION; IFN GAMMA GENE; IL 10 GENE; IL 6 GENE; INFECTION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; NEPHROTOXICITY; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PHARMACOGENOMICS; POSTOPERATIVE COMPLICATION; REVIEW; SCORING SYSTEM; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SODIUM RETENTION; TGF BETA1 GENE; TNF2 GENE; UNSPECIFIED SIDE EFFECT; VEGF GENE;

CYTOKINES; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTORS, CYTOKINE; TRANSPLANTATION IMMUNOLOGY;

EID: 50549096748     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2008.08.002     Document Type: Review

References (80)

1. Kroeger K.M., Carville K.S., and Abraham L.J. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol 34 5 (1997) 391-399
2. Wilson A.G., Symons J.A., McDowell T.L., McDevitt H.O., and Duff G.W. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A 94 7 (1997) 3195-3199
3. Baseggio L., Bartholin L., Chantome A., Charlot C., Rimokh R., and Salles G. Allele-specific binding to the -308 single nucleotide polymorphism site in the tumour necrosis factor-alpha promoter. Eur J Immunogenet 31 1 (2004) 15-19
4. Fishman D., Faulds G., Jeffery R., Mohamed-Ali V., Yudkin J.S., Humphries S., and Woo P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102 7 (1998) 1369-1376
5. Turner D.M., Williams D.M., Sankaran D., Lazarus M., Sinnott P.J., and Hutchinson I.V. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24 1 (1997) 1-8
6. Frossard P.M., Pravica V., Perrey C., Hutchinson I.V., and Lukic M.L. Lack of association between human TGF-beta1 gene variants and primary hypertension. Am J Hypertens 13 8 (2000) 944-945
7. Awad M.R., Webber S., Boyle G., Sturchioc C., Ahmed M., Martell J., Law Y., Miller S.A., Bowman P., Gribar S., et al. The effect of cytokine gene polymorphisms on pediatric heart allograft outcome. J Heart Lung Transplant 20 6 (2001) 625-630
8. Turner D., Grant S.C., Yonan N., Sheldon S., Dyer P.A., Sinnott P.J., and Hutchinson I.V. Cytokine gene polymorphism and heart transplant rejection. Transplantation 64 5 (1997) 776-779. For the first time, this study outlines the importance of studying SNPs in combination, rather than in isolation.
9. Ternstrom L., Jeppsson A., Ricksten A., and Nilsson F. Tumor necrosis factor gene polymorphism and cardiac allograft vasculopathy. J Heart Lung Transplant 24 4 (2005) 433-438
10. Densem C.G., Hutchinson I.V., Yonan N., and Brooks N.H. Influence of tumor necrosis factor-alpha gene-308 polymorphism on the development of coronary vasculopathy after cardiac transplantation. J Heart Lung Transplant 20 12 (2001) 1265-1273
11. Densem C.G., Ray M., Hutchinson I.V., Yonan N., and Brooks N.H. Interleukin-6 polymorphism: a genetic risk factor for cardiac transplant related coronary vasculopathy?. J Heart Lung Transplant 24 5 (2005) 559-565
12. Girnita D.M., Brooks M.M., Webber S.A., Burckart G.J., Ferrell R., Zdanowicz G., DeCroo S., Smith L., Chinnock R., Canter C., et al. Genetic polymorphisms impact the risk of acute rejection in pediatric heart transplantation: a multi-institutional study. Transplantation 85 11 (2008) 1632-1639. Genetic polymorphism combinations as independent predictors for rejection profile in pediatric heart recipients.
13. Girnita D.M., Webber S.A., Ferrell R., Burckart G.J., Brooks M.M., McDade K.K., Chinnock R., Canter C., Addonizio L., Bernstein D., et al. Disparate distribution of 16 candidate single nucleotide polymorphisms among racial and ethnic groups of pediatric heart transplant patients. Transplantation 82 12 (2006) 1774-1780. Racial distribution of 16 SNPs of cytokine, growth factors, cytotoxic molecules, and pharmacogenomic factors in pediatric heart transplanted patients.
14. Brogan I.J., Khan N., Isaac K., Hutchinson J.A., Pravica V., and Hutchinson I.V. Novel polymorphisms in the promoter and 5′ UTR regions of the human vascular endothelial growth factor gene. Hum Immunol 60 12 (1999) 1245-1249
15. Stevens A., Soden J., Brenchley P.E., Ralph S., and Ray D.W. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 63 4 (2003) 812-816
16. Tambur A.R., Pamboukian S., Costanzo M.R., and Heroux A. Genetic polymorphism in platelet-derived growth factor and vascular endothelial growth factor are significantly associated with cardiac allograft vasculopathy. J Heart Lung Transplant 25 6 (2006) 690-698
17. Gourley I.S., Denofrio D., Rand W., Desai S., Loh E., and Kamoun M. The effect of recipient cytokine gene polymorphism on cardiac transplantation outcome. Hum Immunol 65 3 (2004) 248-254
18. Di Filippo S., Zeevi A., McDade K.K., Bastien O., and Webber S.A. Impact of TGFbeta1 gene polymorphisms on acute and chronic rejection in pediatric heart transplant allografts. Transplantation 81 6 (2006) 934-939
19. Densem C.G., Hutchinson I.V., Yonan N., and Brooks N.H. Donor and recipient-transforming growth factor-beta 1 polymorphism and cardiac transplant-related coronary artery disease. Transplant Immunol 13 3 (2004) 211-217
20. Di Filippo S., Cochat P., and Bozio A. The challenge of renal function in heart transplant children. Pediatr Nephrol (Berlin, Germany) 22 3 (2007) 333-342
21. van de Wetering J., Weimar C.H., Balk A.H., Roodnat J.I., Holweg C.T., Baan C.C., van Domburg R.T., and Weimar W. The impact of transforming growth factor-beta1 gene polymorphism on end-stage renal failure after heart transplantation. Transplantation 82 12 (2006) 1744-1748. Large and comprehensive study on the impact of TGF-β1 SNPs and calciuneurin inhibitor-induced end-stage renal failure, following heart transplantation.
22. Di Filippo S., Zeevi A., McDade K.K., Boyle G.J., Miller S.A., Gandhi S.K., and Webber S.A. Impact of TGFbeta1 gene polymorphisms on late renal function in pediatric heart transplantation. Hum Immunol 66 2 (2005) 133-139
23. Zheng H.X., Burckart G.J., McCurry K., Webber S., Ristich J., Iacono A., Dauber J., McDade K., Grgurich W., Zaldonis D., et al. Interleukin-10 production genotype protects against acute persistent rejection after lung transplantation. J Heart Lung Transplant 23 5 (2004) 541-546
24. Lu K.C., Jaramillo A., Lecha R.L., Schuessler R.B., Aloush A., Trulock E.P., Mendeloff E.N., Huddleston C.B., Alexander Patterson G., and Mohanakumar T. Interleukin-6 and interferon-gamma gene polymorphisms in the development of bronchiolitis obliterans syndrome after lung transplantation. Transplantation 74 9 (2002) 1297-1302
25. Snyder L.D., Hartwig M.G., Ganous T., Davis R.D., Herczyk W.F., Reinsmoen N.L., Schwartz D.A., and Palmer S.M. Cytokine gene polymorphisms are not associated with bronchiolitis obliterans syndrome or survival after lung transplant. J Heart Lung Transplant 25 11 (2006) 1330-1335
26. Palmer S.M., Klimecki W., Yu L., Reinsmoen N.L., Snyder L.D., Ganous T.M., Burch L., and Schwartz D.A. Genetic regulation of rejection and survival following human lung transplantation by the innate immune receptor CD14. Am J Transplant 7 3 (2007) 693-699. Innate immune receptor gene polymorphisms can also contribute to the onset and severity of rejection in lung recipients.
27. Tinckam K., Rush D., Hutchinson I., Dembinski I., Pravica V., Jeffery J., and Nickerson P. The relative importance of cytokine gene polymorphisms in the development of early and late acute rejection and six-month renal allograft pathology. Transplantation 79 7 (2005) 836-841. This study outlines the impact of pro-inflammatory cytokine SNPs on various forms of rejection in renal transplantation.
28. Manchanda P.K., and Mittal R.D. Analysis of cytokine gene polymorphisms in recipient's matched with living donors on acute rejection after renal transplantation. Mol Cell Biochem 311 1-2 (2008) 57-65
29. Brabcova I., Petrasek J., Hribova P., Hyklova K., Bartosova K., Lacha J., and Viklicky O. Genetic variability of major inflammatory mediators has no impact on the outcome of kidney transplantation. Transplantation 84 8 (2007) 1037-1044
30. Azarpira N., Aghdaie M.H., Geramizadeh B., Behzadi S., Nikeghbalian S., Sagheb F., Rahsaz M., Behzad-Behbahanie A., Ayatollahi M., Darai M., et al. Cytokine gene polymorphisms in renal transplant recipients. Exp Clin Transplant 4 2 (2006) 528-531
31. Breulmann B., Bantis C., Siekierka M., Blume C., Aker S., Kuhr N., Grabensee B., and Ivens K. Influence of cytokine genes polymorphisms on long-term outcome in renal transplantation. Clin Transplant 21 5 (2007) 615-621
32. Dmitrienko S., Hoar D.I., Balshaw R., and Keown P.A. Immune response gene polymorphisms in renal transplant recipients. Transplantation 80 12 (2005) 1773-1782
33. Nikolova P.N., Ivanova M.I., Mihailova S.M., Myhailova A.P., Baltadjieva D.N., Simeonov P.L., Paskalev E.K., and Naumova E.J. Cytokine gene polymorphism in kidney transplantation-impact of TGF-beta 1, TNF-alpha and IL-6 on graft outcome. Transplant Immunol 18 4 (2008) 344-348
34. Manchanda P.K., Kumar A., Bid H.K., and Mittal R.D. Interleukin-1beta and receptor antagonist (IL-1Ra) gene polymorphisms and the prediction of the risk of end-stage renal disease. Biomarkers 11 2 (2006) 164-173
35. Hueso M., Navarro E., Moreso F., Beltran-Sastre V., Ventura F., Grinyo J.M., and Seron D. Relationship between subclinical rejection and genotype, renal messenger RNA, and plasma protein transforming growth factor-beta1 levels. Transplantation 81 10 (2006) 1463-1466
36. Thakkinstian A., Dmitrienko S., Gerbase-Delima M., McDaniel D.O., Inigo P., Chow K.M., McEvoy M., Ingsathit A., Trevillian P., Barber W.H., et al. Association between cytokine gene polymorphisms and outcomes in renal transplantation: a meta-analysis of individual patient data. Nephrol Dial Transplant (2008). Large meta-analysis that reports the independent effect of HLA-ABDR mismatch, age at the time of transplant, and SNPs on poor outcome in renal recipients.
37. Masuda Y., Shimizu A., Mori T., Ishiwata T., Kitamura H., Ohashi R., Ishizaki M., Asano G., Sugisaki Y., and Yamanaka N. Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am J Pathol 159 2 (2001) 599-608
38. Shahbazi M., Fryer A.A., Pravica V., Brogan I.J., Ramsay H.M., Hutchinson I.V., and Harden P.N. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 13 1 (2002) 260-264
39. Lemos F.B., Mol W.M., Roodnat J.I., Uitterlinden A., Ijzermans J.N., Weimar W., and Baan C.C. The beneficial effects of recipient-derived vascular endothelial growth factor on graft survival after kidney transplantation. Transplantation 79 9 (2005) 1221-1225. Multivariate analysis, including important clinical variables, which correlated one VEGF SNP with better survival.
40. Gunesacar R., Opelz G., Erken E., Pelzl S., Dohler B., Ruhenstroth A., and Susal C. VEGF 936 C/T gene polymorphism in renal transplant recipients: association of the T allele with good graft outcome. Hum Immunol 68 7 (2007) 599-602
41. Warle M.C., Metselaar H.J., Hop W.C., and Tilanus H.W. Cytokine gene polymorphisms and acute liver graft rejection: a meta-analysis. Liver Transpl 11 1 (2005) 19-26. Quantitative meta-analysis of association studies on cytokine gene polymorphism and acute liver allograft rejection.
42. Gomez-Mateo J., Marin L., Lopez-Alvarez M.R., Moya-Quiles M.R., Miras M., Marin-Moreno I., Botella C., Parrilla P., Alvarez-Lopez M.R., and Muro M. TGF-beta1 gene polymorphism in liver graft recipients. Transpl Immunol 17 1 (2006) 55-57
43. Kimball P., Baker M., and Fisher R.A. Allograft TNFbeta and IL16 polymorphisms influence HCV recurrence and severity after liver transplantation. Liver Transpl 12 2 (2006) 247-252
44. Dickinson A.M., Harrold J.L., and Cullup H. Haematopoietic stem cell transplantation: can our genes predict clinical outcome?. Expert Rev Mol Med 9 29 (2007) 1-19. Up-to-date review of the relevant findings related to SNPs impact in hematopoietic stem cell transplantation.
45. Viel D.O., Tsuneto L.T., Sossai C.R., Lieber S.R., Marques S.B., Vigorito A.C., Aranha F.J., de Brito Eid K.A., Oliveira G.B., Miranda E.C., et al. IL2 and TNFA gene polymorphisms and the risk of graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Scand J Immunol 66 6 (2007) 703-710
46. Lin M.T., Storer B., Martin P.J., Tseng L.H., Gooley T., Chen P.J., and Hansen J.A. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 349 23 (2003) 2201-2210. Large cohort of HLA-identical sibling HSCT and IL-10 gene polymorphism impact on GVHD.
47. Azarpira N., Ramzi M., Aghdaie M.H., Darai M., and Geramizadeh B. Interleukin-10 gene polymorphism in bone marrow transplant recipients. Exp Clin Transplant 6 1 (2008) 74-79
48. Cullup H., and Stark G. Interleukin-1 polymorphisms and graft-vs-host disease. Leuk Lymphoma 46 4 (2005) 517-523. The authors provided a detailed review of IL-1 gene polymorphism and GVHD in HSCT.
49. Karabon L., Wysoczanska B., Bogunia-Kubik K., Suchnicki K., and Lange A. IL-6 and IL-10 promoter gene polymorphisms of patients and donors of allogeneic sibling hematopoietic stem cell transplants associate with the risk of acute graft-versus-host disease. Hum Immunol 66 6 (2005) 700-710. Correlation between IL-6 SNP and quantitative assessment of protein in serum and increased risk of acute GVHD.
50. MacMillan M.L., Radloff G.A., DeFor T.E., Weisdorf D.J., and Davies S.M. Interleukin-1 genotype and outcome of unrelated donor bone marrow transplantation. Br J Haematol 121 4 (2003) 597-604
51. Mehta P.A., Eapen M., Klein J.P., Gandham S., Elliott J., Zamzow T., Combs M., Aplenc R., MacMillan M.L., Weisdorf D.J., et al. Interleukin-1 alpha genotype and outcome of unrelated donor haematopoietic stem cell transplantation for chronic myeloid leukaemia. Br J Haematol 137 2 (2007) 152-157
52. Seo K.W., Kim D.H., Sohn S.K., Lee N.Y., Chang H.H., Kim S.W., Jeon S.B., Baek J.H., Kim J.G., Suh J.S., et al. Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation. Bone Marrow Transplant 36 12 (2005) 1089-1095
53. Thervet E., Anglicheau D., Legendre C., Beaune P., Thervet E., Anglicheau D., Legendre C., and Beaune P. Role of pharmacogenetics of immunosuppressive drugs in organ transplantation. Ther Drug Monit 30 2 (2008) 143-150. A review of the current knowledge regarding gene polymorphisms of metabolizing enzymes and transporters of immunosuppressive drugs.
54. Cattaneo D., Baldelli S., and Perico N. Pharmacogenetics of immunosuppressants: progress, pitfalls and promises. Am J Transplant 8 (2008) 1374-1383. A review of recent advances and pitfalls related to pharmacogenetics in organ transplantation.
55. Wojnowski L. Genetics of the variable expression of CYP3A in humans. Ther Drug Monit 26 2 (2004) 192-199
56. Zheng H., Zeevi A., Schuetz E., Lamba J., McCurry K., Griffith B.P., Webber S., Ristich J., Dauber J., Iacono A., et al. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J Clin Pharmacol 44 2 (2004) 135-140
57. Yu S., Wu L., Jin J., Yan S., Jiang G., Xie H., Zheng S., Yu S., Wu L., Jin J., et al. Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. Transplantation 81 1 (2006) 46-51
58. Wei-lin W., Jing J., Shu-sen Z., Li-hua W., Ting-bo L., Song-feng Y., Sheng Y., Wei-lin W., Jing J., Shu-sen Z., et al. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transpl 12 5 (2006) 775-780. The effect of both donor and recipient genotypes on Tacrolimus dosing.
59. Haufroid V., Wallemacq P., VanKerckhove V., Elens L., De Meyer M., Eddour D.C., Malaise J., Lison D., and Mourad M. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am J Transplant 6 11 (2006) 2706-2713
60. Op den Buijsch R.A., Christiaans M.H., Stolk L.M., de Vries J.E., Cheung C.Y., Undre N.A., van Hooff J.P., van Dieijen-Visser M.P., and Bekers O. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam Clin Pharmacol 21 4 (2007) 427-435
61. Ng F.L., Holt D.W., and MacPhee I.A. Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation. Exp Opin Pharmacother 8 13 (2007) 2045-2058
62. Anglicheau D., Legendre C., and Thervet E. Pharmacogenetics of tacrolimus and sirolimus in renal transplant patients: from retrospective analyses to prospective studies. Transplant Proc 39 7 (2007) 2142-2144
63. Kuypers D.R., de Jonge H., Naesens M., Lerut E., Verbeke K., Vanrenterghem Y., and Kuypers D.R.J. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 82 6 (2007) 711-725
64. Zheng H., Webber S., Zeevi A., Schuetz E., Zhang J., Bowman P., Boyle G., Law Y., Miller S., Lamba J., et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 3 4 (2003) 477-483
65. Elens L., Capron A., Kerckhove V.V., Lerut J., Mourad M., Lison D., Wallemacq P., Haufroid V., Elens L., Capron A., et al. 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. Pharmacogenetics Genomics 17 10 (2007) 873-883
66. Sahasranaman S., Howard D., Roy S., Sahasranaman S., Howard D., and Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 64 8 (2008) 753-767
67. Anglicheau D., Thervet E., Etienne I., Hurault De Ligny B., Le Meur Y., Touchard G., Buchler M., Laurent-Puig P., Tregouet D., Beaune P., et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 75 5 (2004) 422-433
68. Fanta S., Niemi M., Jonsson S., Karlsson M.O., Holmberg C., Neuvonen P.J., Hoppu K., and Backman J.T. Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenetics Genomics 18 2 (2008) 77-90. Age-related effect of ABCB1 polymorphism on oral bioavailability of Cyclosporin A.
69. Hauser I.A., Schaeffeler E., Gauer S., Scheuermann E.H., Wegner B., Gossmann J., Ackermann H., Seidl C., Hocher B., Zanger U.M., et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 16 5 (2005) 1501-1511. In a multivariant model, only donor's ABCB1 genotype was strongly associated with Cyclosporin A induced nephrotoxicity.
70. Le Meur Y., Djebli N., Szelag J.C., Hoizey G., Toupance O., Rerolle J.P., and Marquet P. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin Pharmacol Ther 80 1 (2006) 51-60
71. Zheng H., Webber S., Zeevi A., Schuetz E., Zhang J., Lamba J., Bowman P., and Burckart G.J. The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum Immunol 63 9 (2002) 765-770
72. Zheng H.X., Webber S.A., Zeevi A., Schuetz E., Zhang J., Lamba J., Boyle G.J., Wilson J.W., and Burckart G.J. The impact of pharmacogenomic factors on steroid dependency in pediatric heart transplant patients using logistic regression analysis. Pediatr Transpl 8 6 (2004) 551-557
73. Lee S.J., Jusko W.J., Salaita C.G., Calis K.A., Jann M.W., Spratlin V.E., Goldstein J.A., Hon Y.Y., Lee S.-J., Jusko W.J., et al. Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition. J Clin Pharmacol 46 5 (2006) 515-526
74. Hirata T., Fujioka M., Takahashi K.A., Arai Y., Asano T., Ishida M., Kuribayashi M., Akioka K., Okamoto M., Yoshimura N., et al. ApoB C7623T polymorphism predicts risk for steroid-induced osteonecrosis of the femoral head after renal transplantation. J Orthop Sci 12 3 (2007) 199-206
75. Ferraresso M., Tirelli A., Ghio L., Grillo P., Martina V., Torresani E., Edefonti A., Ferraresso M., Tirelli A., Ghio L., et al. Influence of the CYP3A5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients. Pediatr Transpl 11 3 (2007) 296-300 [see comment]
76. Naesens M., Kuypers D.R., Verbeke K., Vanrenterghem Y., Naesens M., Kuypers D.R.J., Verbeke K., and Vanrenterghem Y. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 82 8 (2006) 1074-1084
77. Ohmann E.L., Burckart G.J., Chen Y., Pravica V., Girnita D.M., Brooks M.M., Mowrey D.W., Zeevi A., and Webber S.A. Impact of inosine 5′-monophosphate dehyrogenase 1,2 and multidrug resistance protein 2 genetic polymorphisms on mycophenolate mofetil related adverse events in pediatric heart transplant patients. J Heart Lung Transplant 27 2S (2008) S181
78. Miura M., Satoh S., Inoue K., Kagaya H., Saito M., Inoue T., Suzuki T., Habuchi T., Miura M., Satoh S., et al. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 63 12 (2007) 1161-1169. Association of OATP/SLCO and MRP2/ABCC2 genetic polymorphisms and MPA side effects in renal recipients.
79. Wang J., Zeevi A., Webber S., Girnita D.M., Addonizio L., Selby R., Hutchinson I.V., Burckart G.J., Wang J., Zeevi A., et al. A novel variant L263F in human inosine 5′-monophosphate dehydrogenase 2 is associated with diminished enzyme activity. Pharmacogenetics Genomics 17 4 (2007) 283-290. Identification of a novel non-synonymous variant L263F with significant impact on IMPDH2 activity.
80. Wang J., Yang J.W., Zeevi A., Webber S.A., Girnita D.M., Selby R., Fu J., Shah T., Pravica V., Hutchinson I.V., et al. IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharm Ther 83 5 (2008) 711-717